Literature DB >> 2479047

Clozapine pharmacology and tardive dyskinesia.

J Lieberman1, C Johns, T Cooper, S Pollack, J Kane.   

Abstract

Clozapine, an atypical neuroleptic, does not cause extrapyramidal symptoms of Parkinsonism and dystonia and appears to have a reduced or absent capacity to produce tardive dyskinesia. 37 subjects, most with chronic schizophrenia, were treated with clozapine and TD outcome was analyzed. A subset of these subjects underwent plasma and CSF studies. TD response was heterogenous, but a proportion of patients improved with clozapine treatment. Neurochemical data differed from published reports of classical neuroleptics with the most robust effect produced by clozapine seen in CSF norepinephrine levels. Other neurochemical data and implications for the mechanism of clozapine in TD are reviewed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479047     DOI: 10.1007/bf00442560

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

Review 1.  Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.

Authors:  D P van Kammen; J Peters; W B van Kammen
Journal:  Psychiatr Clin North Am       Date:  1986-03

2.  Clozapine effects on tardive dyskinesia.

Authors:  J A Lieberman; B L Saltz; C A Johns; S Pollack; J M Kane
Journal:  Psychopharmacol Bull       Date:  1989

3.  Biogenic amines in autistic and atypical children. Cerebrospinal fluid measures of homovanillic acid and 5-hydroxyindoleacetic acid.

Authors:  D J Cohen; B A Shaywitz; W T Johnson; M Bowers
Journal:  Arch Gen Psychiatry       Date:  1974-12

4.  A rating scale for extrapyramidal side effects.

Authors:  G M Simpson; J W Angus
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

5.  Prevalence of tardive dyskinesia in elderly samples.

Authors:  J Lieberman; J M Kane; M Woerner; P Weinhold; N Basavaraju; J Kurucz; K Bergmann
Journal:  Psychopharmacol Bull       Date:  1984

6.  Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat.

Authors:  H R Bürki; W Ruch; H Asper; M Baggiolini; G Stille
Journal:  Eur J Pharmacol       Date:  1974-07       Impact factor: 4.432

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

8.  The effects of diet and physical activity on plasma homovanillic acid in normal human subjects.

Authors:  K S Kendler; R C Mohs; K L Davis
Journal:  Psychiatry Res       Date:  1983-03       Impact factor: 3.222

9.  Clozapine blocks disruptive and discriminative stimulus effects of quipazine.

Authors:  R L Friedman; E Sanders-Bush; R L Barrett
Journal:  Eur J Pharmacol       Date:  1984-10-30       Impact factor: 4.432

10.  CSF monoamine metabolites in schizophrenic patients.

Authors:  W F Gattaz; P Waldmeier; H Beckmann
Journal:  Acta Psychiatr Scand       Date:  1982-11       Impact factor: 6.392

  10 in total
  7 in total

1.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Effects of clozapine on CSF homovanillic acid in spasmodic torticollis.

Authors:  A Thiel; D Dressler; A Reimer; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 3.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  High frequency oral movements induced by long-term administration of amperozide but not FG5803 in rats.

Authors:  U Liminga; P E Andren; L S Ohlund; L M Gunne
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

5.  Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic.

Authors:  Paola Devoto; Giovanna Flore; Giada Vacca; Luigi Pira; Alessandra Arca; Maria Antonietta Casu; Luca Pani; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

6.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 7.  Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review.

Authors:  Maria Skokou; Eleni A Karavia; Zoi Drakou; Vassiliki Konstantinopoulou; Christina-Anna Kavakioti; Philippos Gourzis; Kyriakos E Kypreos; Ourania Andreopoulou
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.